<DOC>
	<DOCNO>NCT01110876</DOCNO>
	<brief_summary>Phase I Objectives : -To determine maximum tolerate dose ( MTD ) vorinostat + erlotinib versus vorinostat + erlotinib + temozolomide adult patient recurrent glioblastoma multiforme ( GBM ) anaplastic glioma . Phase II Objectives : Primary : To determine efficacy vorinostat + erlotinib versus vorinostat + erlotinib + temozolomide patient recurrent glioblastoma multiforme progression free survival use two arm adaptive randomization phase II trial design . Secondary : To determine radiological response , progression free survival ( PFS ) 6 month , overall survival unexpected toxicity two treatment arm ; obtain exploratory data regard histone 3 4 acetylation , treatment related change epidermal growth factor receptor ( EGFR ) pathway protein , change e-cadherin vimentin expression ( mRNA /protein ) level tumor tissue peripheral monocyte subset surgical patient .</brief_summary>
	<brief_title>Phase I / II Vorinostat , Erlotinib Temozolomide Recurrent Glioblastoma Multiforme ( GBM )</brief_title>
	<detailed_description>Phase I : The Study Drugs : Vorinostat design cause chemical change different group protein attach DNA ( genetic material cell ) , may slow growth cancer cell cause cancer cell die . Erlotinib design block activity protein find surface many tumor cell may control tumor growth survival . This may stop tumor grow . Temozolomide design kill cancer cell damage DNA ( genetic material cell ) . The damage DNA may cause tumor cell death . Study Groups : There 2 phase study . If find eligible take part Phase I portion study , assign 1 2 group base join study . You remain group entire study . In study , dose level study drug different group group . Up 4 dose level study drug combination test Group 1 , 2 dose level Group 2 . Three ( 3 ) participant enrol dose level . The first 3 participant group receive low dose level . Each 3 new participant receive high dose one , intolerable side effect see . This continue high tolerable dose study drug give combination find . - If Group 1 , take vorinostat , erlotinib , temozolomide . - If Group 2 , take vorinostat erlotinib . In addition , matter group dose level assign , enzyme induce anti-seizure drug , take high dose erlotinib . Study Drug Administration : Each study cycle 28 day . If Group 1 : - On Days 1-7 15-21 every cycle , take vorinostat mouth 2 time day . You take vorinostat food . Do open , crush , chew capsule . - On Days 1-21 every cycle , take erlotinib mouth 1 time day . You take erlotinib morning 1 hour 2 hour food 1 cup ( 8 oz . ) water . - On Days 1-7 15-21of every cycle , take temozolomide mouth 1 time day . You swallow temozolomide capsule whole , one right , without chew . If vomit take temozolomide , take capsule next schedule dose . They take empty stomach ( least 1 hour 2 hour eat ) 1 cup ( 8 ounce ) water . If Group 2 : - On Days 1-14 every cycle , take vorinostat mouth 2 time day . You take vorinostat food . Do open , crush , chew capsule . - On Days 1-21 every cycle , take erlotinib mouth 1 time day . You take erlotinib morning 1 hour 2 hour food 1 cup ( 8 oz . ) water . Study Visits : Every 4 week first 8 week , every 8 week : - Your complete medical history record . - You ask drug may take experienced side effect . - You physical exam , include measurement vital sign weight . - You neurological exam . - Your performance status record . Every week first 4 week , every 2 week , blood ( 3 teaspoon ) draw routine test check blood 's ability clot normally . Every 4 week , anti-seizure drug , blood ( 1 teaspoon ) drawn measure amount anti-seizure drug blood . Every 8 week , MRI scan check status disease . Length Study : You study 1 year . You may continue receive study drug beyond 1 year remain study doctor decide best interest . You take study early disease get bad experience intolerable side effect . Long-Term Follow-Up Visit : If go study 12 cycle , blood ( 3 teaspoon ) draw routine test check blood 's ability clot normally every 2 week 30 day last dose study drug . If go study reason worsen disease , MRI every 2 month unless disease get bad . If MRI show worsen disease , every 2-3 month , may call ask feel new cancer treatment may receive . This phone call take 5-10 minute . This investigational study . Erlotinib FDA approve drug treatment type non-small cell lung cancer , temozolomide type brain cancer , vorinostat type lymphoma . All commercially available . The use drug combination investigational . Up 182 participant take part study . Up 72 patient enroll Phase 1 portion study . All enrol MD Anderson . Phase II : The Study Drugs : Vorinostat design cause chemical change different group protein attach DNA ( genetic material cell ) , may slow growth cancer cell cause cancer cell die . Erlotinib design block activity protein find surface many tumor cell may control tumor growth survival . This may stop tumor grow . Temozolomide design kill cancer cell damage DNA ( genetic material cell ) . The damage DNA may cause tumor cell death . Study Groups : There 2 phase study . If find eligible take part Phase 2 portion study , randomly assign ( roll dice ) 1 2 group . - If Group 1 , take vorinostat erlotinib . - If Group 2 , take vorinostat , erlotinib , temozolomide . Subset Group : If doctor recommend surgery remove tumor come back , eligible subset group . You would surgery assign main study group . This subset group study do learn effect vorinostat tumor tissue blood cell . Before surgery , randomly assign 1 3 group . - If Group A , receive vorinostat alone . - If Group B , receive erlotinib alone . - If Group C , receive vorinostat erlotinib . You take study drug ( ) 3 day row surgery . About 2 week surgery , randomly assign 1 2 main study group describe ( Group 1 2 ) . In addition , matter group assign , enzyme induce anti-seizure drug , take high dose erlotinib . Study Drug Administration : Every cycle 28 day . If Group 1 : - On Days 1-14 every cycle , take vorinostat mouth 2 time day . You take vorinostat food . Do open , crush , chew capsule . - On Days 1-21 every cycle , take erlotinib mouth 1 time day . You take erlotinib morning 1 hour 2 hour food 1 cup ( 8 oz . ) water . If Group 2 : - On Days 1-7 15-21 every cycle , take vorinostat mouth 2 time day .You take vorinostat food . Do open , crush , chew capsule . - On Days 1-21 every cycle , take erlotinib mouth 1 time day . You take erlotinib morning 1 hour 2 hour food 1 cup ( 8 oz . ) water . - On Days 1-7 15-21 every cycle , take temozolomide mouth 1 time day . You swallow temozolomide capsule whole , one right , without chew . If vomit take temozolomide , take capsule next schedule dose . They take empty stomach ( least 1 hour 2 hour eat ) 1 cup ( 8 ounce ) water . Subset group : For 3 day row surgery : - If Group A , take vorinostat mouth 2 time day . - If Group B , take erlotinib mouth 1 time day . - If Group C , take vorinostat mouth 2 time day erlotinib mouth 1 time day . After recovered effect surgery ( 2 week ) , follow study group schedule ( Group 1 2 ) describe . Study Visits : Every 4 week first 8 week , every 8 week : - Your complete medical history record . - You ask drug may take side effect . - You physical exam , include measurement vital sign weight . - You neurological exam . - Your performance status record . Every week first 4 week , every 2 week , blood ( 3 teaspoon ) draw routine test check blood 's ability clot normally . Every 4 week , anti-seizure medication , blood ( 1 teaspoon ) drawn measure amount anti-seizure medication blood . Every 8 week , MRI scan check status disease . Subset Group : In addition test , blood ( 1 teaspoon time ) draw 1 time 3 time first dose vorinostat , surgery . This blood use study drug level , effect drug normal blood cell , match finding tumor . After surgery , part leftover tumor tissue surgery use measure drug level effect vorinostat tumor use biomarker test . Length Study : You study 1 year . You may continue receive treatment beyond 1 year remain study doctor decide best interest . You take study early disease get bad intolerable side effect . Long-Term Follow-Up Visit : If go study 12 cycle , blood ( 3 teaspoon ) draw routine test check blood 's ability clot normally every 2 week 30 day last dose study drug . If go study reason worsen disease , MRI every 2 month unless disease get bad . If MRI show worsen disease , every 2-3 month , may call ask feel new cancer treatment may receive . This phone call take 5-10 minute . This investigational study . Erlotinib FDA approve drug treatment type non-small cell lung cancer , temozolomide type brain cancer , vorinostat type lymphoma . All commercially available . The use drug combination investigational . Up 182 participant take part study . Up 110 patient enrol Phase 2 portion study . Up 15 participant take part subset portion study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Brain Neoplasms</mesh_term>
	<mesh_term>Temozolomide</mesh_term>
	<mesh_term>Vorinostat</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Dacarbazine</mesh_term>
	<criteria>1 . Patients histologically proven glioblastoma multiforme , gliosarcoma anaplastic glioma eligible Phase I component . Anaplastic glioma include anaplastic astrocytoma ( AA ) , anaplastic oligodendroglioma ( AO ) , anaplastic oligoastrocytoma ( AOA ) , malignant glioma otherwise specify ( NOS ) . Patients eligible original histology lowgrade glioma subsequent histological diagnosis malignant glioma make . Only patient histologically prove supratentorial glioblastoma multiforme gliosarcoma eligible Phase II component . 2 . Patients must show unequivocal evidence tumor recurrence progression MRI scan fail radiation therapy . Patients complete radiation therapy least 3 month prior entry study . The scan do prior study entry document progression review treat physician document change tumor dimension confirm recurrence . 3 . ( 2. continue ) Patients prior therapy include interstitial brachytherapy stereotactic radiosurgery must reasonable confirmation true progressive disease rather radiation necrosis determine treat physician neuroradiologist ; example , MRI , magnetic resonance ( MR ) spectroscopy , PET scan brain . 4 . For Phase I component , number prior relapse allow , provide patient fulfills eligibility criterion particularly functional status . For phase II component , patient may 2 prior relapse 5 . All patient must sign informed consent indicate awareness investigational nature study keep policy hospital . 6 . The baseline onstudy MRI perform within 14 day ( +/ 3 day ) prior registration steroid dosage stable decrease least 5 day . If steroid dose increase date imaging initiation therapy ( time ) , new baseline MRI require . The type scan , i.e. , MRI , must use throughout period protocol treatment tumor measurement . 7 . Patients undergone recent resection recurrent progressive tumor eligible long follow condition apply : ) They recover effect surgery . b ) Evaluable measurable disease follow resection recurrent tumor mandate eligibility study . c ) To best assess extent residual measurable disease postoperatively , MRI do later 96 hour immediate postoperative period 46 week postoperatively . 8 . Patients must 18 year old old . 9 . Patients must Karnofsky performance status ( KPS ) equal great 60 10 . Patients must recover toxic effect prior therapy grade 1 non hematological &lt; /= grade 2 hematological toxicity ( except deep vein thrombosis ) : 4 week prior cytotoxic therapy bevacizumab and/or least two week vincristine , 6 week nitrosoureas , 3 week procarbazine administration , 1 week noncytotoxic agent , e.g. , interferon , tamoxifen , cisretinoic acid , etc . ( radiosensitizer count ) . 11 . ( 10. continue ) Patients receive anticancer agent nontherapeutic purpose unrelated study ( presurgically obtain pharmacology data agent ) eligible enter study provide recover toxic effect agent . Any question relate definition noncytotoxic agent direct Study Chair . 12 . Patients must adequate bone marrow function ( ANC &gt; /= 1,500/mm^3 platelet count &gt; /= 100,000/mm^3 ) , adequate liver function ( SGPT &lt; /= 3 time normal alkaline phosphatase &lt; /= 2 time normal , bilirubin &lt; /= 1.5 mg/dl ) , adequate renal function ( BUN creatinine &lt; /= 1.5 time institutional normal ) prior registration . 13 . Women childbearing potential treatment must pregnant , must breastfeed must practice adequate contraception . Male patient treatment vorinostat must agree use adequate method contraception duration study , 30 day last dose study medication . 1 . Patients history cancer ( except nonmelanoma skin cancer carcinoma insitu cervix bladder ) , unless complete remission therapy disease minimum 3 year ineligible . 2 . Patients must : ) active infection b ) disease obscure toxicity dangerously alter drug metabolism , especially liver disease include cirrhosis hepatic dysfunction c ) serious intercurrent medical illness 3 . Patients currently active treatment AIDS hepatitis exclude due potential adverse interaction ongoing treatment agent unknown toxicity . 4 . Patients receive valproic acid ( VPA ) , anticonvulsant drug histone deacetylase ( HDAC ) inhibitor property , exclude , unless switch alternative agent prior treatment initiation . A 5 day wash period require . 5 . Prior treatment EGFR inhibitor temozolomide standard day 15 dose low dose daily dose part chemoradiation therapy allow trial base hypothesis combination agent use synergistic effect , HDAC inhibition potentially overcome resistance EGFR inhibitor temozolomide . However , prior treatment dose dense regimen temozolomide ( 7 day on/ 7 day , 21 days/28 day continuous low dose daily dose chemoradiation ) HDAC inhibitor valproic acid ( depsipeptide , LBH589 vorinostat ) permit . 6 . Patients know allergy component vorinostat , know allergy Temozolomide erlotinib exclude . 7 . Patient must able tolerate procedure require study include periodic blood sampling , study related assessment , management treat institution duration study . Inability comply protocol study procedure ( example , inability swallow tablet ) exclusion criterion . 8 . This study design include woman minority , design measure difference intervention effect . Males female recruit preference gender . 9 . No exclusion study base race . The malignant glioma patient population treat MD Anderson Cancer Center ( MDACC ) past year follow : American Indian Alaskan Native 0 ; Asian Pacific Islander &lt; 2 % ; Black , Hispanic Origin 3 % ; Hispanic 6 % ; White , Hispanic Origin 88 % ; Other Unknown 2 % ; Total100 % .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2014</verification_date>
	<keyword>Recurrent Glioblastoma Multiforme</keyword>
	<keyword>GBM</keyword>
	<keyword>Brain</keyword>
	<keyword>Central Nervous Center</keyword>
	<keyword>Malignant glioma</keyword>
	<keyword>Glioblastoma multiforme</keyword>
	<keyword>Gliosarcoma</keyword>
	<keyword>Anaplastic astrocytoma</keyword>
	<keyword>Anaplastic oligodendroglioma</keyword>
	<keyword>Anaplastic oligoastrocytoma</keyword>
	<keyword>Vorinostat</keyword>
	<keyword>SAHA</keyword>
	<keyword>Suberoylanilide Hydroxamic Acid</keyword>
	<keyword>MSK-390</keyword>
	<keyword>Zolinza</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>Erlotinib Hydrochloride</keyword>
	<keyword>OSI-774</keyword>
	<keyword>Tarceva</keyword>
	<keyword>Temozolomide</keyword>
	<keyword>Temodar</keyword>
</DOC>